ArticleSurgery today2026
Laboratory frailty index in pancreaticoduodenectomy: short-term safety and long-term prognosis.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe Laboratory Frailty Index (FI-lab), derived from routine preoperative laboratory parameters, offers a simple and objective alternative to conventional frailty assessment. However, its clinical relevance in elderly patients undergoing pancreaticoduodenectomy (PD), particularly those with pancreatic ductal adenocarcinoma (PDAC), remains unclear.
methodsWe retrospectively analyzed 350 patients aged ≥ 65 years who underwent PD between 2012 and 2021. Frailty was defined as FI-lab ≥ 0.40. Short-term outcomes, including major postoperative complications (Clavien-Dindo grade ≥IIIa) and in-hospital mortality, were compared between frail and non-frail patients. The long-term outcomes (overall survival [OS] and disease-free survival [DFS]) were evaluated in 166 patients with PDAC.
resultsNinety-seven patients (27.7%) were classified as frail. Frail patients had a lower body mass index, greater intraoperative blood loss, and higher transfusion rates, whereas major complications and mortality rates were comparable between the groups. In patients with PDAC, frailty was associated with shorter OS (27.5 vs. 42.2 months; p = 0.043) and DFS (16.7 vs. 23.4 months; p = 0.046), although it was not an independent prognostic factor.
conclusionsFI-lab-defined frailty was not associated with perioperative morbidity or mortality after PD. In patients with PDAC, FI-lab may serve as a supplementary tool for preoperative risk stratification by reflecting their physiological vulnerability.
Indexed as
Identifiers
42217001What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.